Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04577807 · ClinicalTrials.gov registry record · Phase 2
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
A Phase 2 study, sponsored by Istari Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT04577807 is a Phase 2 study that has completed, run by Istari Oncology. The registered enrollment target is 27 participants.
The verdict
NCT04577807, a Phase 2 study, has completed, sponsored by Istari Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
Interventions
- BIOLOGICAL Lerapolturev
- BIOLOGICAL Anti-PD-1 Checkpoint Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04577807
The ClinicalTrials.gov registry entry for NCT04577807 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Istari Oncology, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lerapolturev is the first listed.
NCT04577807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04577807 about?
NCT04577807 is a clinical study titled "LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma". A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
What is the current status of trial NCT04577807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2020-11-17. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT04577807?
The interventions under investigation include: Lerapolturev (BIOLOGICAL), Anti-PD-1 Checkpoint Inhibitor (BIOLOGICAL).
Who is sponsoring clinical trial NCT04577807?
This trial is sponsored by Istari Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.